Pick Up the (Patent Process) Pace!

A common frustration for patent applicants is the incredibly slow pace at which an application proceeds from filing to receipt of a substantive examination report to allowance. On average it takes 15.7 months for a patent application to receive even a first substantive examination report! The Patent Office has recognized this problem and implemented several initiatives which …

Continue reading Pick Up the (Patent Process) Pace!

Is Software Patentable?

By: Brian J. Assessor On June 19, 2014, the Supreme Court’s decision in Alice Corp. v. CLS Bank International sent shockwaves through many areas of patent law and, as a result of that decision, patent attorneys, inventors, and companies working in the computer and software space are wondering “is software patentable?” and, if so, “what type …

Continue reading Is Software Patentable?

USPTO Reduces Certain Trademark Filing Fees

By: Tom Dunn On January 17, 2015, the USPTO reduced certain trademark filing fees and introduced a new electronic application filing option. The fee for both the TEAS Plus application and the TEAS Regular application are reduced by $50. The TEAS Reduced Fee (TEAS RF) application is a new filing option, and one may still …

Continue reading USPTO Reduces Certain Trademark Filing Fees

FDA Releases Guidance for Determining Biologic Exclusivity Under the BPCI Act

By: David Fazzolare & Joanna Brougher On August 4, 2014, the Food & Drug Administration (FDA) released its latest guidance in a series of guidance documents issued as part of its ongoing effort toward implementing a biosimilar approval pathway under the Biologics Price Competition and Innovation Act of 2009 (BPCI Act).  In contrast to previously …

Continue reading FDA Releases Guidance for Determining Biologic Exclusivity Under the BPCI Act

Biosimilars Developers Watch Closely as FDA Accepts First Biosimilar Application from Sandoz

By: David Fazzolare & Joanna Brougher Sandoz, a Novartis Group company, announced on July 24, 2014 that the US Food and Drug Administration (FDA) has accepted for review its application for a biosimilar version of filgrastim. The reference product, Neupogen®, which brought maker Amgen Inc. $1.4 billion in sales in 2013, is a biologic used …

Continue reading Biosimilars Developers Watch Closely as FDA Accepts First Biosimilar Application from Sandoz